MSB 1.34% $1.51 mesoblast limited

Mergers and acquisitions, page-2

  1. 4,196 Posts.
    lightbulb Created with Sketch. 5495
    Based on the markets' reaction to the news.....zero. I don't think the company would entertain anything either given we have an upcoming phase 3 ARDS to be released , phase 3 back and the heart failure phase 3 to be looked at ... and the Crohns trial also running in the US.. and the Novartis partnership.

    It's pretty clear the company is looking to partner rather than be taken over.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.